Hans Prenen
Department of General Medical Oncology
University Hospital Gasthuisberg
Catholic University Leuven
Herestraat 49
Belgium
Name/email consistency: high
- New therapeutic developments in renal cell cancer. Prenen, H., Gil, T., Awada, A. Crit. Rev. Oncol. Hematol. (2009)
- Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets. Prenen, H., Kimpe, M., Nuyts, S. Curr. Opin. Oncol (2008)
- Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial. Prenen, H., Dumez, H., Stefan, C., Hoeben, A., Wouters, C., Van Lierde, M.A., Sciot, R., van Oosterom, A.T., Peeters, M., Polus, M., Duck, L., Gil, T., Schöffski, P. Acta Gastroenterol. Belg. (2006)
- Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Prenen, H., Guetens, G., de Boeck, G., Debiec-Rychter, M., Manley, P., Schoffski, P., van Oosterom, A.T., de Bruijn, E. Pharmacology (2006)
- Everolimus alters imatinib blood partition in favour of the erythrocyte. Prenen, H., Guetens, G., De Boeck, G., Highley, M., van Oosterom, A.T., de Bruijn, E.A. J. Pharm. Pharmacol. (2006)
